1. Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo group
- Author
-
Joanne Lynn, T. Murray, S. Bansil, Robert P. Lisak, H. S. Panitch, M. Lajaunie, Michael Wall, K. Lloyd, N. Simonian, E. Carter, D. Patry, D. Bolibrush, Paul O'Connor, S. Cooper Hanel, A. Gulati, Stanley A. Hashimoto, Dennis Bourdette, J. Brillman, Lloyd H. Kasper, Trevor A. Gray, M. Kupersmith, Dusan Stefoski, Claudia F. Lucchinetti, R. P. Kinkel, A. Walker, C. Miller, K. White, R. J. Whaley, C. Gustafson, James L. Bernat, Christopher T. Bever, J. O'Bannon, Jeffrey A. Cohen, L. Cappolino, H. Park, A. Wallin, W. Tyor, S. Peters, K. Ryan, J. Javerbaum, Staley A. Brod, M. Shepard, G. Glista, A. Cajade-Law, P. Fleming, T. Bental, J. Ware, Jonathan Goldstein, C. Brownscheidle, Melvin Greer, H. Rabinowicz, D. Pfohl, J. Lehrich, C. Coon, G. Donneief, Gilles P Bernier, Michele Mass, V. Bhan, M. Yeung, J. Kline, U. Webb, B. Richardson, D. Kuder, S. Horowitz, D. Singel, P. Weldon, Pierre Duquette, W. Sibley, John Guy, C. Yardley, Steven Galetta, M. Meyer, Luanne M. Metz, W. Morrison, E. Holzemer, Lawrence W. Myers, T. Anderson, D. L. Chandler, Alexandros Tselis, D. Stuart, R. Burger, Carlo Tornatore, B. Muntz, M. Camasso, T. Scott, L. Durcan, Jack H. Simon, Jerry S. Wolinsky, B. Apatoff, T. Johnson, S. E. Jackson, Frederick Munschauer, Timothy Vollmer, S. Wray, J. Astruc, Douglas L. Arnold, L. Kerson, D. Court, R. Arnoutelis, W. Brown, W. Stuart, K. Karlin, S. Thurston, K. Costello, L. Scheller, Lawrence Jacobs, E. Bastings, G. Birnbaum, T. Hedges, Stephen C. Reingold, T. Grabowski, Warren L. Felton, P. Mandalfino, M. Butler, A. Blumenfeld, John W. Rose, C. Kung, Douglas Jeffery, Richard J. Caselli, Stuart D. Cook, N. Blanchard, R. Leek, B. Ehrenberg, P. Slasor, F. Votruba, E. Cerretta, J. Buckner, Kottil Rammohan, G. Liu, A. Siffort, Andrew D. Goodman, B. Quandt, L. Pappert, Joseph Guarnaccia, J. McGee, A. Bonnett, D. McHugh, D. Jacobson, John B. Selhorst, G. Rice, T. Tran, Eric R. Eggenberger, S. Hamilton, Jonathan L. Carter, Stephen R. Cole, Michael Kaufman, R. Burde, L. Vining, Roy W. Beck, J. Cooper, D. Mattson, P. Pennell, C. Griffin, J. Warner, S. Putnam, A. Jotkowitz, J. Gilmore, J. Friedman, P. Sexton, D. E. Miller, M. Reiss, John H. Noseworthy, J. Herbert, J. Burns, D. Snider, J. Rosenberg, Nancy J. Newman, M. Botten, M. Petrie, Joel Oger, John R. Richert, M. Wilson, E. Escott, R. Dubois, Loren A. Rolak, A. Sandrock, James Goodwin, J. Antel, B. Coombs, Mark S. Freedman, Craig H. Smith, G. Hayat, D. Bartlett, David I. Kaufman, J. Brown, A. Miller, C. E. Maxner, and C. Orapello
- Subjects
Adult ,Male ,medicine.medical_specialty ,Multiple Sclerosis ,Time Factors ,Placebo group ,Disease activity ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Brain mri ,Medicine ,Humans ,Multicenter Studies as Topic ,030212 general & internal medicine ,business.industry ,Multiple sclerosis ,Brain ,medicine.disease ,Prognosis ,Magnetic Resonance Imaging ,Term (time) ,Neurology ,Physical therapy ,Female ,Neurology (clinical) ,Controlled Clinical Trials as Topic ,business ,Event analysis ,030217 neurology & neurosurgery ,Demyelinating Diseases - Abstract
We evaluated 190 patients in the placebo group of the CHAMPS trial in order to assess factors associated with short-term clinical and brain magnetic resonance imaging (MRI) outcomes in patients with a first clinical demyelinating event involving the optic nerve, spinal cord, or brainstem/cerebellum, and subclinical demyelination on brain MRI. The two study outcomes were 1) development of clinically definite multiple sclerosis (CDMS) and 2) development of CDMS or two or more new or enlarging brain MRI T2 lesions. The presence of gadolinium (Gd)- enhancing lesions on the baseline scan was the only MRI characteristic associated with a higher risk of both the clinical and combined outcomes (p=0.003 and
- Published
- 2002